Bioxyne (ASX:BXN) — Material Events
ASX:BXN · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Bioxyne Surges with Record $17.2M Revenue and Expands Global ReachHigh
Bioxyne posts record $17.2M revenue, expands international footprint, and launches GMP MDMA capsules
28 Jan 2026
·Quarterly Activities Report
·90
Bioxyne Ltd H1 FY26 Revenue Surges 149% on Medicinal Cannabis and Psychedelic DemandHigh
Bioxyne Ltd H1 FY26 revenue surges 149%, net profit doubles on strong medicinal cannabis and psychedelics demand
26 Feb 2026
·Appendix 4D – Half Year Report
·90
Bioxyne Surges with Record $17.2M Revenue, Expands Psychedelic and Cannabis ReachHigh
Bioxyne posts record Q2 revenue, expands international footprint, and advances psychedelics supply
28 Jan 2026
·Quarterly Activities Report
·90
Bioxyne Surges with Record $17.2M Q2 Revenue, Eyes $75M FY26 TargetMedium
Bioxyne posts record Q2 FY26 revenue $17.2M, expands into UK and Europe, raises FY26 guidance
29 Jan 2026
·Quarterly Results Presentation
·85
Bioxyne Secures $50 Million German Supply Deal with ADREXpharmaMedium
Bioxyne inks $50 million exclusive German supply deal with ADREXpharma
12 May 2026
·Major Contract Announcement
·85
Bioxyne Surges with Record $14.1M Q1 Revenue, Eyes European ExpansionMedium
Bioxyne posts record Q1 FY26 revenue, reconfirms FY26 guidance amid strong European expansion
30 Oct 2025
·Quarterly Results Presentation
·85
Bioxyne Secures Exclusive Rights to Launch Curaleaf’s Medical Cannabis Inhaler in AustraliaMedium
Bioxyne Secures Exclusive Deal to Launch Curaleaf Medical Cannabis Inhaler in Australia
3 Nov 2025
·ASX Announcement
·85
Bioxyne Surges with Record $14.1M Q1 Revenue, Eyes European ExpansionMedium
Bioxyne posts record Q1 revenue, expands European footprint with Frankfurt listing
30 Oct 2025
·Quarterly Activities Report
·85
Bioxyne Partners with Aurora Cannabis to Expand Global Medicinal SupplyMedium
Bioxyne Signs Manufacturing Deal with Aurora Cannabis to Supply Medicinal Cannabis Products Globally
1 Apr 2026
·Major Contract Announcement
·85
Bioxyne Breaks Ground with First Cannabis Supply Deal in Central AmericaMedium
Bioxyne Secures First-Mover Cannabis Supply Deal in Central America
11 Dec 2025
·Major Contract Announcement
·80
Bioxyne Secures £850k to Launch UK Medicinal Cannabis FacilityMedium
Bioxyne secures £850k funding to open UK GMP cannabis manufacturing site
17 Nov 2025
·ASX Announcement
·80
Bioxyne Breaks New Ground with First Medicinal Cannabis Flower Supply to Costa RicaMedium
Bioxyne expands LATAM supply agreement to include medicinal cannabis flower in Costa Rica
11 May 2026
·Supply Agreement Expansion
·80
Bioxyne Advances German Market with A$5.1M Medical Cannabis OrdersMedium
Bioxyne Secures German Import Permits and A$5.1M Medical Cannabis Orders
15 Sept 2025
·Business Update
·80
No articles in this tier for the last 12 months.
Market Mentions
9
- appeared in market wrap coverage
These are market wrap articles where Bioxyne (ASX:BXN) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 20 (11 May -> 15 May) 2026
16 May 2026
Market Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Market Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026